Literature DB >> 19774949

Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer.

Erina Kansakar1, Yeon-Jeen Chang, Massoud Mehrabi, Vijay Mittal.   

Abstract

Thyroid cancer is three times more prevalent in females but the role of sex hormones in its pathogenesis is unknown. Vascular endothelial growth factor (VEGF) is crucial for angiogenesis. Its expression correlates with tumor aggressiveness and metastatic potential. We determined the expression of estrogen receptor (ER), progesterone receptor (PR), and VEGF-A in thyroid neoplasms to see if expression correlated with age and sex, histological type, cancer stage, and clinical outcome. Pathological samples of thyroid cancer diagnosed from 2002 to 2007 were stained immunohistochemically for ER, PR, and VEGF-A. Grading was done qualitatively in intensity and quantitatively in percentage. Both grades were multiplied to assign a final score. One hundred and four patients were studied, of which 82 per cent were female with a mean age of 53 years (range 23-86 years). Most tumors were papillary in origin. Overall, final scores were significantly higher for ER (1.41) and PR (1.0) in tumors compared with the ER (1.07) and PR (0.42) in normal tissue (P = 0.005 and < 0.001, respectively). Conversely, VEGF-A had lower expression in tumor tissues (7.2) than in normal tissue (8.2) (P = 0.024). No predilection was found for specific age group, gender, histological subtype, or stage of the cancer. Thus, compared with normal tissue, ER and PR expression is higher and VEGF-A expression is lower in tumor thyroid tissue. The overexpression of sex hormone receptors in thyroid tumor suggests their role in thyroid cancer pathogenesis and needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19774949

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  12 in total

1.  Validation of reference genes for normalizing gene expression in real-time quantitative reverse transcription PCR in human thyroid cells in primary culture treated with progesterone and estradiol.

Authors:  Ana Paula Santin; Aline Francielle Damo Souza; Llma Simoni Brum; Tania Weber Furlanetto
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

2.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

3.  Vitamin D receptor and progesterone receptor protein and gene expression in papillary thyroid carcinomas: associations with histological features.

Authors:  M P Yavropoulou; G Panagiotou; K Topouridou; G Karayannopoulou; T Koletsa; T Zarampoukas; A Goropoulos; E Chatzaki; J G Yovos; K Pazaitou-Panayiotou
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

4.  The association of menstrual and reproductive factors with thyroid nodules in Chinese women older than 40 years of age.

Authors:  Kun Wang; Yu Yang; Yang Wu; Jie Chen; Danyu Zhang; Chao Liu
Journal:  Endocrine       Date:  2014-07-11       Impact factor: 3.633

5.  Estrogen receptor- and progesterone receptor-positive diffuse sclerosing variant of papillary thyroid carcinoma: a case report.

Authors:  Yuichi Kinoshita; Kosho Takasu; Takashi Yuri; Kastuhiko Yoshizawa; Yuko Emoto; Airo Tsubura; Nobuaki Shikata
Journal:  Case Rep Oncol       Date:  2013-04-06

6.  VEGF-C Is a Thyroid Marker of Malignancy Superior to VEGF-A in the Differential Diagnostics of Thyroid Lesions.

Authors:  Kosma Woliński; Adam Stangierski; Ewelina Szczepanek-Parulska; Edyta Gurgul; Bartłomiej Budny; Elzbieta Wrotkowska; Maciej Biczysko; Marek Ruchala
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 7.  Overlapping nongenomic and genomic actions of thyroid hormone and steroids.

Authors:  Stephen R Hammes; Paul J Davis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-04-22       Impact factor: 4.690

8.  Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma.

Authors:  Marwa Mohammed Serag Eldien; Asmaa Gaber Abdou; Tarek Rageh; Eman Abdelrazek; Enas Elkholy
Journal:  Ecancermedicalscience       Date:  2017-06-13

9.  LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer.

Authors:  Lu Lu; Xueli Yuan; Qiang Zhang; Hong Zhang; Baozhong Shen
Journal:  Mol Med Rep       Date:  2017-02-28       Impact factor: 2.952

10.  Expression of estrogen and progesterone receptors in papillary thyroid carcinoma.

Authors:  Mohammad-Reza Jalali-Nadoushan; Reza Amirtouri; Ali Davati; Samaneh Askari; Sepideh Siadati
Journal:  Caspian J Intern Med       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.